You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Expected Nov 7, Pre-Market